Seraph Awarded Diagnostic Development Initiative Grant

(DETROIT) – Seraph Biosciences, Inc. (“Seraph”), creator of Seraspec®, was recently awarded promotional credits from Amazon Web Services (“AWS”) as part of its Diagnostic Development Initiative. In the wake of the COVID-19 pandemic, the AWS Diagnostic Development Initiative is committing $20 million in credits and technical support to support innovation in patient testing and other diagnostic solutions for COVID-19 and to mitigate future outbreaks. This funding will support Seraph’s continued development Seraspec®, a medical diagnostic device that is lightweight, portable and can provide a pathogen ID (virus, bacteria) in real time at the point of care (POC) by using Raman Spectroscopy. Seraph believes that the support and resources offered by AWS will bolster the company’s research and development efforts while bringing Seraspec® one step closer to providing clinicians the information they need to avert future public health crises.